Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
133 shown of 9,725 total abstracts
  1. Abstract 42482026-04-05 · 14:30 CT · S406
    Quality of life outcomes with Tecentriq in patients with HCC
    T. Mok, M. Reck, J. Cortes, et al. · Karolinska Institute
    Education SessionGastrointestinal Cancer📄🖼️
  2. Abstract 94292026-04-05 · 13:00 CT · S406
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-349
    L. Paz-Ares, H. Borghaei, A. Spira, et al. · Cleveland Clinic
    Education SessionLung Cancer—Small Cell📄🖼️
  3. Abstract 55052026-04-05 · 15:15 CT · Arie Crown Theater
    OlympiA-112: Lynparza (olaparib) maintenance in prostate
    N. Rizvi, A. Spira, G. Curigliano, et al. · University of Chicago
    Education SessionGenitourinary Cancer—Prostate📄🖼️
  4. Abstract 41502026-04-02 · 15:45 CT · E450
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    M.C. Garassino, A. Spira, S. Antonia, et al. · University of Chicago
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 10172026-04-02 · 18:15 CT · E450
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-895
    N. Rizvi, S. Modi, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 15892026-04-02 · 14:45 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    J. Brahmer, E. Winer · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 45642026-04-01 · 15:15 CT · S406
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-954 study)
    L. Paz-Ares, F. Andre · Cleveland Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract 10722026-04-01 · 21:30 CT · Hall B1
    PALOMA-315: Ibrance (palbociclib) maintenance in HR+ breast cancer
    H. Rugo, J. Brahmer, R. Herbst, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 10162026-04-02 · 21:15 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-708
    J. Brahmer, G. Curigliano, S. Antonia, et al. · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 16962026-04-05 · 18:15 CT · S406
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    C. Robert, S. Antonia, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 17242026-04-01 · 15:45 CT · S406
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    R. Herbst, L. Paz-Ares, N. Rizvi, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 45762026-04-03 · 18:00 CT · S100A
    EV-142: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    S. Antonia, S. Peters, M. Krop · Chinese University of Hong Kong
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  13. Abstract 98232026-04-01 · 18:45 CT · S100A
    Quality of life outcomes with Imfinzi in patients with SCLC
    A. Spira, M.C. Garassino, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Small Cell📄🖼️
  14. Abstract 17052026-04-05 · 20:00 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    G. Curigliano, F. Andre, E. Winer · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 17492026-04-04 · 13:45 CT · Hall B1
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    T. Mok, C. Robert, M.C. Garassino · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 17202026-04-03 · 15:30 CT · Hall B1
    PALOMA-458: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    C. Robert, R. Herbst, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 14222026-04-05 · 16:15 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-97
    S. Antonia, L. Paz-Ares, S. Tolaney · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 19602026-04-04 · 16:30 CT · S406
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-370
    S. Antonia, J. Brahmer, H. Borghaei, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 93992026-04-05 · 14:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-156
    M. Reck, P. Schmid, S. Tolaney, et al. · Mayo Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 42862026-04-01 · 21:30 CT · Hall B1
    Long-term follow-up of Imfinzi 2L for biliary tract: PACIFIC-990
    M. Krop, E. Winer, N. Rizvi, et al. · Karolinska Institute
    Education SessionGastrointestinal Cancer📄🖼️
  21. Abstract 92592026-04-04 · 20:45 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    M. Krop, S. Peters, C. Saura, et al. · Vall d'Hebron Institute of Oncology
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 15782026-04-03 · 13:45 CT · S100A
    Quality of life outcomes with Tecentriq in patients with TNBC
    L. Paz-Ares, H. Rugo · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 93772026-04-01 · 13:15 CT · E450
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-582
    A. Spira, G. Curigliano, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Small Cell📄🖼️
  24. Abstract 97982026-04-01 · 19:45 CT · S100A
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    C. Saura, S. Antonia, T. Mok · Mayo Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  25. Abstract 11962026-04-05 · 21:15 CT · S406
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    F. Andre, P. Schmid, E. Winer · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 13992026-04-02 · 21:30 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-151 study)
    H. Rugo, N. Rizvi, S. Peters, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 56162026-04-05 · 19:15 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in prostate
    S. Tolaney, S. Antonia, L. Paz-Ares · Massachusetts General Hospital
    Education SessionGenitourinary Cancer—Prostate📄🖼️
  28. Abstract 95052026-04-05 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-496 study)
    S. Tolaney, T. Mok, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  29. Abstract 92502026-04-02 · 21:45 CT · S406
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-76
    S. Antonia, F. Andre · Karolinska Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  30. Abstract 14222026-04-04 · 14:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-705 study)
    H. Rugo, L. Paz-Ares, R. Herbst, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 97162026-04-02 · 18:30 CT · E450
    Long-term follow-up of Keytruda 3L+ for SCLC: KEYNOTE-155
    H. Rugo, R. Herbst, S. Tolaney · Institut Gustave Roussy
    Education SessionLung Cancer—Small Cell📄🖼️
  32. Abstract 60892026-04-04 · 14:30 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with RCC
    J. Brahmer, G. Curigliano, M. Reck, et al. · Institut Gustave Roussy
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  33. Abstract 14202026-04-03 · 13:45 CT · S406
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-97
    N. Rizvi, A. Spira · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 10412026-04-03 · 16:00 CT · S406
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-900
    F. Andre, C. Saura, S. Tolaney · University of Chicago
    Education SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 57952026-04-05 · 19:45 CT · S406
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-157
    M. Krop, L. Paz-Ares, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionGynecologic Cancer📄🖼️
  36. Abstract 91982026-04-04 · 16:45 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    C. Saura, M.C. Garassino, E. Winer · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  37. Abstract 91162026-04-03 · 13:30 CT · E450
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    A. Spira, M. Krop · Chinese University of Hong Kong
    Education SessionLung Cancer—Small Cell📄🖼️
  38. Abstract 46512026-04-02 · 21:00 CT · S100A
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-810 study)
    J. Cortes, S. Antonia · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionGastrointestinal Cancer📄🖼️
  39. Abstract 61822026-04-05 · 21:00 CT · S100A
    Long-term follow-up of Lynparza 1L for ovarian: OlympiA-554
    H. Rugo, S. Antonia, N. Rizvi, et al. · Karolinska Institute
    Education SessionGynecologic Cancer📄🖼️
  40. Abstract 40032026-04-03 · 18:00 CT · S100A
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-308 study)
    N. Rizvi, J. Brahmer · Vall d'Hebron Institute of Oncology
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  41. Abstract 18642026-04-03 · 16:30 CT · Hall B1
    MONALEESA-998: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    H. Rugo, P. Schmid, S. Modi · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 14862026-04-01 · 19:15 CT · S406
    MONALEESA-279: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    A. Spira, M.C. Garassino, S. Antonia · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 99972026-04-01 · 14:45 CT · E450
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-69 study)
    F. Andre, T. Mok · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  44. Abstract 55852026-04-05 · 18:45 CT · E450
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-302
    J. Cortes, S. Antonia · Memorial Sloan Kettering Cancer Center
    Education SessionGenitourinary Cancer—Prostate📄🖼️
  45. Abstract 97212026-04-05 · 14:15 CT · S406
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-411 study)
    H. Borghaei, N. Rizvi, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  46. Abstract 43712026-04-05 · 13:00 CT · E450
    CheckMate-49: Opdivo (nivolumab) neoadjuvant in HCC
    E. Winer, A. Spira, J. Brahmer, et al. · Stanford Cancer Institute
    Education SessionGastrointestinal Cancer📄🖼️
  47. Abstract 44762026-04-03 · 16:30 CT · Arie Crown Theater
    EV-429: Padcev (enfortumab vedotin) 3L+ in urothelial carcinoma
    F. Andre, R. Herbst, P. Schmid, et al. · Karolinska Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  48. Abstract 98332026-04-01 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 3L+ for NSCLC: KEYNOTE-147
    S. Tolaney, F. Andre, R. Herbst · Vall d'Hebron Institute of Oncology
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  49. Abstract 98432026-04-05 · 18:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-409
    M. Krop, S. Modi, R. Herbst · Peter MacCallum Cancer Centre
    Education SessionLung Cancer—Small Cell📄🖼️
  50. Abstract 10892026-04-04 · 13:15 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-741 study)
    N. Rizvi, E. Winer, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 94712026-04-03 · 13:15 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    S. Antonia, S. Tolaney, M. Reck, et al. · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  52. Abstract 43202026-04-04 · 16:30 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi maintenance for biliary tract: PACIFIC-511
    H. Borghaei, L. Paz-Ares, A. Spira, et al. · Massachusetts General Hospital
    Education SessionGastrointestinal Cancer📄🖼️
  53. Abstract 42862026-04-04 · 21:45 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    G. Curigliano, S. Antonia · MD Anderson Cancer Center
    Education SessionGastrointestinal Cancer📄🖼️
  54. Abstract 68952026-04-03 · 21:45 CT · S100A
    Quality of life outcomes with Opdivo in patients with RCC
    T. Mok, A. Spira, C. Saura · Stanford Cancer Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  55. Abstract 14712026-04-04 · 14:30 CT · Hall B1
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-661
    R. Herbst, E. Winer, F. Andre, et al. · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 18692026-04-02 · 18:00 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-125 study)
    M. Krop, C. Robert, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract 12492026-04-01 · 19:45 CT · Arie Crown Theater
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    H. Borghaei, C. Saura, S. Antonia · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract 10412026-04-05 · 20:45 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-347 study)
    C. Saura, G. Curigliano, M. Reck · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 11242026-04-03 · 20:45 CT · S100A
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-779
    H. Rugo, T. Mok · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  60. Abstract 95022026-04-01 · 19:15 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-746 study)
    S. Antonia, T. Mok, M. Reck, et al. · Stanford Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  61. Abstract 14952026-04-01 · 15:30 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-741 study)
    G. Curigliano, N. Rizvi, H. Borghaei, et al. · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 45142026-04-04 · 13:30 CT · S100A
    Long-term follow-up of Padcev 2L for urothelial carcinoma: EV-784
    G. Curigliano, M. Krop, P. Schmid, et al. · Peter MacCallum Cancer Centre
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  63. Abstract 95982026-04-05 · 13:15 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-250
    N. Rizvi, S. Tolaney, T. Mok, et al. · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  64. Abstract 42732026-04-04 · 13:45 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    H. Rugo, P. Schmid, C. Robert, et al. · Mayo Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  65. Abstract 17772026-04-04 · 16:00 CT · Hall B1
    Long-term follow-up of Lynparza neoadjuvant for HR+ breast cancer: OlympiA-914
    N. Rizvi, F. Andre, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 97752026-04-04 · 14:00 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-72
    T. Mok, S. Antonia · Cleveland Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  67. Abstract 40822026-04-02 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in HCC (the CheckMate-19 study)
    M. Reck, C. Robert · Peter MacCallum Cancer Centre
    Education SessionGastrointestinal Cancer📄🖼️
  68. Abstract 48872026-04-01 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-411 study)
    J. Brahmer, M.C. Garassino, H. Borghaei, et al. · Massachusetts General Hospital
    Education SessionGastrointestinal Cancer📄🖼️
  69. Abstract 13772026-04-05 · 21:30 CT · Hall B1
    PALOMA-574: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    H. Rugo, J. Cortes · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 46212026-04-05 · 18:00 CT · E450
    Long-term follow-up of Padcev 2L for urothelial carcinoma: EV-521
    A. Spira, T. Mok, C. Saura, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  71. Abstract 13422026-04-02 · 15:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-350 study)
    F. Andre, S. Antonia, C. Robert · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  72. Abstract 94622026-04-02 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-171
    R. Herbst, E. Winer, P. Schmid · Mayo Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  73. Abstract 99612026-04-01 · 16:45 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-186
    S. Antonia, A. Spira, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  74. Abstract 19732026-04-01 · 20:00 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-693 study)
    L. Paz-Ares, N. Rizvi, S. Peters · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 93792026-04-03 · 15:45 CT · E450
    FLAURA-863: Tagrisso (osimertinib) 1L in NSCLC
    J. Cortes, C. Saura, S. Tolaney, et al. · Peter MacCallum Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  76. Abstract 96522026-04-05 · 16:45 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-347
    T. Mok, A. Spira, S. Modi · MD Anderson Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  77. Abstract 11972026-04-04 · 15:15 CT · E450
    MONALEESA-209: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    P. Schmid, S. Antonia, S. Peters, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  78. Abstract 99712026-04-03 · 14:00 CT · S406
    Quality of life outcomes with Keytruda in patients with NSCLC
    J. Brahmer, C. Saura, P. Schmid, et al. · Karolinska Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  79. Abstract 46712026-04-04 · 15:30 CT · E450
    DESTINY-Breast-473: Enhertu (trastuzumab deruxtecan) 2L in gastric
    S. Antonia, M.C. Garassino, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionGastrointestinal Cancer📄🖼️
  80. Abstract 12592026-04-05 · 15:15 CT · S100A
    OlympiA-708: Lynparza (olaparib) adjuvant in HR+ breast cancer
    T. Mok, P. Schmid · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 18982026-04-04 · 15:30 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    H. Borghaei, E. Winer, J. Cortes · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 18002026-04-05 · 16:00 CT · S406
    OlympiA-260: Lynparza (olaparib) adjuvant in HR+ breast cancer
    N. Rizvi, M. Reck, M. Krop · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 103282026-04-05 · 19:30 CT · E450
    Long-term follow-up of Opdivo adjuvant for metastatic melanoma: CheckMate-838
    G. Curigliano, S. Peters · Johns Hopkins Kimmel Cancer Center
    Education SessionMelanoma📄🖼️
  84. Abstract 17142026-04-04 · 15:00 CT · S406
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    A. Spira, M.C. Garassino, S. Antonia · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 67862026-04-05 · 18:45 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-406 study)
    T. Mok, N. Rizvi, C. Robert, et al. · Karolinska Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  86. Abstract 94382026-04-03 · 21:30 CT · E450
    Long-term follow-up of Tecentriq 3L+ for NSCLC: IMpower-745
    H. Rugo, M. Reck, P. Schmid, et al. · Mayo Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  87. Abstract 15122026-04-02 · 13:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-660
    S. Peters, N. Rizvi, P. Schmid · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  88. Abstract 96552026-04-01 · 13:45 CT · E450
    FLAURA-193: Tagrisso (osimertinib) 3L+ in NSCLC
    G. Curigliano, C. Robert, S. Peters, et al. · Chinese University of Hong Kong
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  89. Abstract 94802026-04-03 · 15:15 CT · E450
    Long-term follow-up of Imfinzi neoadjuvant for NSCLC: PACIFIC-892
    M. Reck, S. Modi, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  90. Abstract 14512026-04-01 · 21:45 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-199
    M. Krop, S. Antonia, H. Borghaei, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract 18662026-04-01 · 15:00 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-31 study)
    M. Krop, S. Tolaney, R. Herbst, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 49882026-04-01 · 16:30 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with HCC
    F. Andre, H. Rugo, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Education SessionGastrointestinal Cancer📄🖼️
  93. Abstract 94992026-04-04 · 15:30 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-654 study)
    M. Krop, N. Rizvi · Stanford Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  94. Abstract 44992026-04-01 · 20:00 CT · S100A
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    C. Robert, S. Modi, S. Tolaney, et al. · University of Chicago
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  95. Abstract 19432026-04-03 · 15:15 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-718
    E. Winer, S. Tolaney, G. Curigliano · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 92772026-04-02 · 15:15 CT · Hall B1
    PACIFIC-587: Imfinzi (durvalumab) 2L in NSCLC
    R. Herbst, A. Spira · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  97. Abstract 18982026-04-05 · 20:30 CT · S406
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-813
    M. Krop, H. Rugo, C. Saura · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract 91752026-04-03 · 16:00 CT · S100A
    PACIFIC-249: Imfinzi (durvalumab) 1L in NSCLC
    M. Krop, S. Peters, M.C. Garassino · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  99. Abstract 46392026-04-04 · 21:45 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-959
    F. Andre, A. Spira · Chinese University of Hong Kong
    Education SessionGastrointestinal Cancer📄🖼️
  100. Abstract 102702026-04-03 · 13:30 CT · S406
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    R. Herbst, F. Andre, C. Robert, et al. · Karolinska Institute
    Education SessionMelanoma📄🖼️
  101. Abstract 60992026-04-05 · 15:15 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in RCC
    F. Andre, S. Peters, M. Krop, et al. · Stanford Cancer Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  102. Abstract 49522026-04-05 · 21:15 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    J. Cortes, R. Herbst, H. Rugo · Peter MacCallum Cancer Centre
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  103. Abstract 19672026-04-01 · 20:30 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-19 study)
    S. Peters, J. Cortes, T. Mok, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  104. Abstract 99402026-04-03 · 14:00 CT · Hall B1
    Long-term follow-up of Imfinzi 3L+ for SCLC: PACIFIC-40
    M.C. Garassino, H. Borghaei, H. Rugo, et al. · Mayo Clinic
    Education SessionLung Cancer—Small Cell📄🖼️
  105. Abstract 13922026-04-02 · 18:00 CT · S100A
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    J. Cortes, S. Peters, T. Mok, et al. · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 44062026-04-05 · 21:15 CT · E450
    Long-term follow-up of Tecentriq maintenance for HCC: IMpower-742
    C. Robert, M. Reck, S. Tolaney, et al. · Institut Gustave Roussy
    Education SessionGastrointestinal Cancer📄🖼️
  107. Abstract 14812026-04-04 · 18:15 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-864
    S. Tolaney, M. Reck, S. Peters, et al. · University of Chicago
    Education SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 98702026-04-01 · 18:15 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-149 study)
    S. Antonia, G. Curigliano, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  109. Abstract 99802026-04-01 · 18:45 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-886
    A. Spira, P. Schmid · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  110. Abstract 93052026-04-03 · 13:00 CT · S100A
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-135
    C. Robert, S. Tolaney, M. Reck, et al. · Institut Gustave Roussy
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  111. Abstract 11102026-04-05 · 20:15 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-229 study)
    C. Robert, F. Andre, P. Schmid, et al. · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 19532026-04-01 · 14:45 CT · S100A
    Long-term follow-up of Tecentriq 1L for TNBC: IMpower-977
    J. Cortes, A. Spira, T. Mok, et al. · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 19222026-04-04 · 21:45 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-928
    S. Tolaney, S. Peters, L. Paz-Ares, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract 42852026-04-03 · 16:30 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-971
    M. Krop, J. Cortes, E. Winer · Cleveland Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  115. Abstract 94972026-04-02 · 15:15 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    R. Herbst, S. Modi, J. Brahmer · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  116. Abstract 17552026-04-05 · 18:00 CT · Hall B1
    MONALEESA-252: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    C. Saura, N. Rizvi, F. Andre · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  117. Abstract 14552026-04-03 · 18:45 CT · S100A
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    J. Brahmer, C. Saura, S. Tolaney · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  118. Abstract 56302026-04-02 · 16:45 CT · Hall B1
    OlympiA-239: Lynparza (olaparib) adjuvant in ovarian
    S. Antonia, S. Tolaney, J. Brahmer · University of Chicago
    Education SessionGynecologic Cancer📄🖼️
  119. Abstract 19452026-04-01 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-130 study)
    T. Mok, A. Spira, S. Antonia, et al. · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  120. Abstract 17322026-04-03 · 21:15 CT · S100A
    PALOMA-673: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    G. Curigliano, T. Mok, H. Rugo, et al. · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract 45322026-04-04 · 16:15 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-518
    M.C. Garassino, J. Cortes · National Cancer Center Japan
    Education SessionGastrointestinal Cancer📄🖼️
  122. Abstract 41352026-04-01 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-359 study)
    M. Reck, S. Antonia · MD Anderson Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  123. Abstract 99252026-04-03 · 18:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-970
    M. Reck, G. Curigliano, P. Schmid, et al. · Institut Gustave Roussy
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  124. Abstract 17782026-04-02 · 18:45 CT · E450
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-327 study)
    L. Paz-Ares, F. Andre, M. Krop, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 47512026-04-02 · 16:00 CT · E450
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-232
    H. Borghaei, F. Andre · Chinese University of Hong Kong
    Education SessionGastrointestinal Cancer📄🖼️
  126. Abstract 92802026-04-01 · 13:15 CT · Hall B1
    FLAURA-91: Tagrisso (osimertinib) adjuvant in NSCLC
    E. Winer, N. Rizvi, C. Saura, et al. · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  127. Abstract 17402026-04-02 · 19:00 CT · Hall B1
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-628
    C. Saura, H. Borghaei, M. Reck, et al. · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 12802026-04-03 · 21:45 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-639 study)
    J. Brahmer, M. Krop, S. Peters, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 10072026-04-02 · 15:15 CT · Hall B1
    MONARCH-655: Verzenio (abemaciclib) 1L in HR+ breast cancer
    R. Herbst, A. Spira, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 16122026-04-03 · 13:00 CT · Hall B1
    Long-term follow-up of Lynparza 1L for HR+ breast cancer: OlympiA-516
    M. Reck, C. Robert · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 11932026-04-03 · 18:00 CT · S406
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-396
    S. Modi, P. Schmid · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  132. Abstract 65212026-04-03 · 16:30 CT · S406
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-855
    G. Curigliano, A. Spira, T. Mok · University of Chicago
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  133. Abstract 60522026-04-02 · 19:30 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    P. Schmid, S. Antonia, C. Saura · Peter MacCallum Cancer Centre
    Education SessionGynecologic Cancer📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.